Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 3,008 shares traded hands during mid-day trading, a decline of 41% from the previous session's volume of 5,088 shares.The stock last traded at $7.78 and had previously closed at $7.56.
Wall Street Analyst Weigh In
PHAR has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday, October 24th. Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, October 28th.
View Our Latest Research Report on PHAR
Pharming Group Trading Up 2.2 %
The firm has a market capitalization of $523.65 million, a P/E ratio of -29.69 and a beta of 0.05. The business's 50 day moving average is $8.21 and its two-hundred day moving average is $8.15. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
